Research Program. Precision Nutrition and Cancer

Clinical Oncology Group

Group leader: Dr. Enrique Casado Sánz and Dr. Jaime Feliú Batle

Objectives: Cancer is a complex disease, whose characteristics, prognosis and response to different treatments depends on several factors, including the patient’s genome, environmental causes such as exposure to contaminants, and microenvironmental causes such as nutritional status or immunological condition of the patient; This complexity makes it imperative that cancer research must be done in a  multidisciplinary way and with the joint efforts of many researchers.

Under the premise that diet and lifestyle are key factors in both cancer prevention and treatment, and in close collaboration with the other groups that are part of the Precision Nutrition and Cancer Program, the Clinical Oncology Group focuses its work on research in patient groups that voluntarily accept to participate in the study of new methods of treating cancer. In general, it is accepted that in the last decades the continuous improvement of the results in the treatment of cancer is due to the realization of clinical trials with new drugs. Similarly, our line of research focused in cancer-oriented nutrigenomics aims to deepen in the knowledge of this pathology by studying highly efficiency products and personalized strategies focused on the implementation of a Precision Nutrition that complements individualized cancer treatments. To do this, we design and carry out clinical trials and nutritional studies that seek to find better ways to prevent, diagnose and treat cancer.

Dr. Enrique Casado Sánz

Director of the Medical Oncology Department, Infanta Sofía University Hospital and Oncology Coordinating Professor of Oncology, European University of Madrid Associate researcher, IMDEA Food Group leader of the Clinical Oncology Group.

Enrique Casado finished his undergraduate studies in Medicine
and Surgery (1992) and Biohealth Sciences (1993) in  complutense University of Madrid (Universidad Complutense de Madrid) (UCM). He obtained the Degree of Doctor of Medicine (1994) with Extraordinary Prize granted by UCM. He did his medical residency in La Paz University Hospital (Hospital Universitario de la Paz) (1993-97) and Master’s Degree in Palliative Care (1997) in Universidad Autónoma de Madrid (UAM), in combination with extended postdoctoral internships in University of Alabama (Birmingham) and University of California (San Francisco). He was the attending physician of Medical Oncology in gastrointestinal and thoracic cancer and laboratory coordinator for the Translational Oncology Group of Hospital Universitario de la Paz
(Madrid), He is an associate professor of UAM and visiting professor of UCM. He is currently the Director of Medical Oncology Department at the Hospital Universitario Infanta Sofía de Madrid and a Coordinating Professor of Oncology in the Universidad Europea de Madrid. He has received 7 awards in recognition of his research work from institutions as prestigious as the American Society of Clinical Oncology.

Dr. Jaime Feliú Batlle

Director of the Medical Oncology Department, La Paz University Hospital and Professor of Oncology in the Medicine Faculty and Director of Master’s Degree in Palliative Care and Treatments for Cancer Patient Support at Universidad Autónoma de Madrid Associate researcher, IMDEA Food Group leader of the Clinical Oncology Group

Dr. Jaime Feliú Batlle holds a Degree in Medicine and Surgery from Universidad Complutense de Madrid issued in 1982. He specialized in Medical Oncology in Hospital Universitario de la Paz, where he is currently the Director of Medical Oncology Department. He is a professor of Oncology in the Medicine Area of Universidad Autónoma de Madrid (UAM) and Director of Master’s Degree in Palliative Care and Treatments for Cancer Patient Support of UAM. Furthermore, he is the current president of the Multidisciplinary Spanish Group of Digestive Cancer (GEMCAD).He has participated as a principal investigator or co-investigator in more than 70 phase I, II and III trials.
He has written or co-written more than 200 articles for national and international journals, more than 60 book chapters and has presented a arge number of communications in national and international congresses.



Members

most relevant publications
  • Cejas P, Cavazza A, Yandava C, Moreno V, Horst D, Moreno- Rubio J, Burgos E, Mendiola M, Taing L, Goel A, Feliu J, Shivdasani RA. Transcriptional regulator CNOT3 defines an aggressive colorectal cancer subtype. Cancer Res. 2017 Feb 1;77(3):766-779.
  • Cejas P, Li L, O’Neill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016 Jun;22(6):685-91.
  • Casado E, García VM, Sánchez JJ, Blanco M, Maurel J, Feliu J, Fernández-Martos C, de Castro J, Castelo B, Belda-Iniesta C, Sereno M, Sánchez-Llamas B, Burgos E, García-Cabezas MÁ, Manceñido N, Miquel R, García-Olmo D, González-Barón M, Cejas P. A combined strategy of SAGE and quantitative PCR provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clinical Cancer Research. 17 - 12, pp. 4145 - 4154. AACR, 2011.
  • Ramírez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Tarón M, Ramírez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, García-Cabezas MA, Sánchez JJ, Nistal M, Rosell R, González-Barón M, Lacal JC. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. The lancet oncology. 8 - 10, pp. 889 - 897. Elsevier, 2007.
  • Belda-Iniesta C, Perona R, de Castro Carpeno J, Chattopadhyay S, Casado E, Cejas P, Fresno Vara JA, Moreno Guerra C, Gonzalez Baron M. Do beta-tubulin pseudogenes really matter?. The Lancet Oncology. 5 - 5, pp. 271 - 272. Elsevier, 2004. Impact Factor: 31,194. Q1, D1.
main research grants

Principal Investigator: Enrique Casado Sáenz
Project Title: Estudio de volátiles en el aliento para el diagnóstico precoz del cáncer colorrectal
Date: 2014-2015
Funded by: Ministerio de Economía y Competitividad.Programa Estatal de investigación, desarrollo e innovación orientada a los retos de la sociedad (AGL2016-76736-C3-3-R)

___________

Principal Investigator: Enrique Casado Sáenz
Project Title: Validación de una firma génica predictiva de respuesta en cáncer de recto (FIS PI11/02695)
Date: 2012-2015
Funded by: Centro para el Desarrollo Tecnológico Industrial (CDTI). Ministerio de Economía y Competitividad (CDTI IDI 20141213)

___________

Principal Investigator: María Sereno Moyano
Project Title: dentificación de marcadores genéticos predictivos de neurotoxicidad de oxaliplatino (FIS PI17-00087)
Date: 2013-2016
Funded by: Consejería de Educación e Investigación. Comunidad de Madrid (ALIBIRD III P2013/ABI-2728)

___________

Principal Investigator: Jaime Feliu Batlle
Project Title: Análisis de biomarcadores relacionados con la eficacia de las terapias dirigidas al cáncer colorectal (FIS PI13/01659)
Date: 2014-2017
Funded by: Programa CIEN, Centro para el Desarrollo Tecnológico Industrial. Ministerio de Economía y Competitividad

___________

Principal Investigator: Guillermo Reglero
Co-Participant Institutions: Hospital Universitario Infanta Sofía Hospital Universitario La Paz
Project Title: Alimentos funcionales y estrategias nutricionales eficaces para la prevención y tratamiento de enfermedades crónicas (ALIBIRD III)
Date: 2014-2018
Funded by: Consejería de Educación e Investigación. Comunidad de Madrid (ALIBIRD III P2013/ABI-2728)

___________